

## Communications to the Editor

[Chem. Pharm. Bull.]  
[32(4)1650—1653(1984)]

AN EFFICIENT PHOSPHORYLATING AGENT FOR THE SYNTHESIS OF NUCLEOSIDE  
3'-PHOSPHODIESTER INTERMEDIATES IN OLIGONUCLEOTIDE SYNTHESIS

Souichi Ueda and Hiroshi Takaku\*

Laboratory of Organic Chemistry, Chiba Institute of Technology,  
Tsudanuma, Narashino, Chiba 275, Japan

By using 3-chloro-1,2-benzisothiazole 1,1-dioxide (BIDCl), 5-chloro-8-quinolyl phosphate can be converted into an efficient phosphorylating agent (4), which can be used to synthesize nucleoside 3'-phosphodiester intermediates (2).


KEYWORDS — phosphorylation; phosphorylating agent; 3-chloro-1,2-benzisothiazole 1,1-dioxide; nucleoside 3'-phosphodiester; nucleotide

Oligonucleotide synthesis by the phosphotriester approach necessitates two separate phosphorylation steps. The first step includes the phosphorylation of a free 3'-hydroxyl group of nucleoside or oligonucleotide to form a phosphodiester linkage. The second step involves the condensation of a partially protected nucleoside or oligonucleotide with a free 5'-hydroxyl group with a 3'-phosphodiester to form a phosphotriester.<sup>1)</sup> Therefore, the nucleoside 3'-phosphodiester derivative is a key intermediate for the synthesis of oligonucleotide by the phosphotriester approach. In our studies<sup>2)</sup> on the synthesis of oligonucleotides by the phosphotriester approach, we used the 5-chloro-8-quinolyl phosphate-coupling agent, 8-quinolinesulfonyl chloride (QS) or 4-chlorophenyl 5-chloro-8-quinolyl phosphorotetrazolide as phosphorylating agents for the synthesis of nucleoside 3'-phosphodiester intermediates. A number of phosphorylating agents have been proposed and applied to the phosphorylation of 3'-hydroxyl group of nucleosides or oligonucleotides.<sup>3)</sup> However, aryl dihydrogen phosphates-coupling agents and aryl phosphorodichloridates (or ditriazolides) are liable to cause the formation of by-products such as 3'-3' dinucleoside monophosphates or sulfonylated nucleotides.<sup>4)</sup> In order to overcome this problem, we developed a new phosphorylating agent (4) prepared simply from 3-chloro-1,2-benzisothiazole 1,1-dioxide (BIDCl)<sup>5)</sup> and 5-chloro-8-quinolyl phosphate.<sup>6)</sup>

Phosphorylation of 5'-O-dimethoxytrityl-N-protected nucleosides (1) with 5-chloro-8-quinolyl phosphate using BIDCl was performed as follows: Addition of BIDCl (4 mol eq) to a dry pyridine solution of 5'-O-dimethoxytritylthymidine (1a) (1 mol eq) and 5-chloro-8-quinolyl phosphate (2 mol eq) afforded 5'-O-dimethoxytritylthymidine 3'-(5-chloro-8-quinolyl) phosphate (2a) in 80% yield along with 3<sup>7)</sup> (7%), and 6% of 1a was recovered. In order to suppress this by-product 3, 5-chloro-8-quinolyl phosphate was treated with BIDCl at first and 1 was added, and the products were subjected to hydrolysis to give the corresponding phosphodiesters 2 in good yields without formation of 3. A typical procedure is as follows: 5-chloro-8-quinolyl phosphate (519 mg, 2.0 mmol) was added to a stirred

solution of BIDCl (850 mg, 4.0 mmol) in dry pyridine (12 ml), and kept for 15 min at room temperature. The  $^{31}\text{P}$ -NMR spectra of the reaction mixture indicated that complete formation of the phosphorylating agent 4 had occurred.<sup>8)</sup> The nucleoside 1a (544 mg, 1.0 mmol) was then added to a stirred solution of 4. After 30 min at room temperature, TLC analysis showed complete conversion of the starting material 1a into the intermediate 5a (Rf 0.61  $\rightarrow$  0.02,  $\text{CH}_2\text{Cl}_2$ -MeOH, 9:1, v/v). It is noted that no side reaction products such as 3'-3' dinucleoside monophosphates and 3 were observed. The reaction mixture was quenched with aqueous triethylamine, and kept for 30 min at room temperature. The solution was poured into a separating funnel with  $\text{CH}_2\text{Cl}_2$  and washed with 0.1M-triethylammonium bicarbonate (TEAB) and with water. The organic layer was dried over  $\text{Na}_2\text{SO}_4$ , concentrated to 5 ml, and added by drops to hexane-ether (9:1, v/v, 200 ml). A white precipitate was collected and dried over  $\text{P}_2\text{O}_5$  in vacuo to give triethylammonium salt (842 mg, 95%) of 2a.

In a similar manner, the 3'-phosphodiester of  $\text{N}^6$ -benzoyldeoxyadenosine (2b),  $\text{N}^4$ -benzoyldeoxycytidine (2c), and  $\text{N}^2$ -isobutyryldeoxyguanosine (2d) were obtained in 94%, 95%, and 92% yields, respectively. The nucleoside 3'-phosphodiester 2 were isolated as white solids, uncontaminated with 5-chloro-8-quinolyl phosphate as indicated by  $^{31}\text{P}$ -NMR.<sup>9)</sup> In addition, no side reactions<sup>4)</sup> on the guanine nucleus was detected in the phosphorylation of 1d. The use of 4-chlorophenyl phosphate<sup>10)</sup> in place of 5-chloro-8-quinolyl phosphate also gave 5'-O-dimethoxy-trityl-N-protected deoxyribonucleoside 3'-(4-chlorophenyl) phosphates in 93-95% yields.



Next, we examined whether the formation of phosphotriester linkage was possible by using the intermediate 5. The intermediate 5 was treated with nucleoside component in dry pyridine, but the phosphotriester linkage formation did not proceed.

The results indicate that the phosphorylating agent 4 can be prepared readily from 5-chloro-8-quinolyl phosphate and  $\text{BIDCl}$  which is a useful phosphorylating agent for the formation of selective phosphodiester linkages. The nucleoside 3'-phosphodiesters are key intermediates for the liquid phase and solid phase synthesis by the phosphotriester approach.

**ACKNOWLEDGEMENT** We thank Professor Tsujiaki Hata of Tokyo Institute of Technology for measurements of  $^{31}\text{P}$ -NMR spectra.

#### REFERENCES AND NOTES

- 1) R. L. Letsinger and K. K. Ogilvie, *J. Am. Chem. Soc.*, **89**, 4801 (1967); F. Eckstein and I. Rizk, *Chem. Ber.*, **102**, 2362 (1969); F. Cramer and J. C. Catlin, *J. Org. Chem.*, **38**, 245 (1974); K. Itakura, N. Katagiri, and S. A. Narang, *Can. J. Chem.*, **52**, 3689 (1974).
- 2) H. Takaku, T. Nomoto, R. Yamaguchi, and T. Hata, *Tetrahedron Lett.*, **1979**, 3357; H. Takaku, M. Kato, M. Yoshida, and R. Yamaguchi, *J. Org. Chem.*, **45**, 3347 (1980); H. Takaku, T. Nomoto, and K. Kamaike, *Chem. Lett.*, **1981**, 543; H. Takaku and M. Yoshida, *J. Org. Chem.*, **46**, 589 (1981).
- 3) For recent reviews, see R. I. Zhadanov and S. M. Zhenodarova, *Synthesis*, **1975**, 222; H. Kössel and H. Seliger, *Prog. Chem. Org. Prod.*, **32**, 297 (1975); V. Amarnath and A. D. Boom, *Chem. Rev.*, **77**, 183 (1977); C. B. Reese, *Tetrahedron*, **34**, 3143 (1978); M. Ikehara, E. Ohtsuka, and A. F. Markham, *Ad. Carbohydr. Chem. Biochem.*, **36**, 135 (1978); E. Ohtsuka, M. Ikehara, and D. Söll, *Nucleic Acids Res.*, **10**, 6553 (1982).
- 4) C. B. Reese and R. Safhill, *J. Chem. Soc., Chem. Commun.*, **1968**, 767; K. Itakura, N. Katagiri, C. P. Bahl, R. H. Wightmann, and S. A. Narang, *J. Am. Chem. Soc.*, **97**, 7327 (1975); J. B. Chattopadhyaya and C. B. Reese, *Tetrahedron Lett.*, **1979**, 5059; J. H. M. de Rooij, G. Welle-Hazelgers, P. H. van Deursen, J. Serdijin, and J. H. van Boom, *Recl. Trav. Chim. Pays-Bas*, **98**, 537 (1979); C. B. Reese and A. Ubasawa, *Tetrahedron Lett.*, **21**, 2265 (1980); B. Rayer, C. B. Reese, and A. Ubasawa, *J. Chem. Soc., Chem. Commun.*, **1980**, 972; P. H. Daskalov, M. Sekine, and T. Hata, *Tetrahedron Lett.*, **21**, 3899 (1980); W. L. Sung, *Nucleic Acids Res.*, **9**, 6139 (1981); H. Takaku, K. Kamaike, and K. Kasuga, *Chem. Lett.*, **1982**, 197; E. Ohtsuka, A. Yamane, and M. Ikehara, *Nucleic Acids Res.*, **11**, 1325 (1982).
- 5) J. A. Jesurn, *Chem. Ber.*, **26**, 2286 (1893); I. R. Meadon and E. E. Reid, *J. Am. Chem. Soc.*, **65**, 457 (1943); H. Hettler, *Tetrahedron Lett.*, **1966**, 1265; H. Somer and F. Cramer, *Chem. Ber.*, **107**, 24 (1974); K. Inomata, H. Kinoshita, H. Fukuda, O. Miyano, Y. Yamashiro, and H. Kotake, *Chem. Lett.*, **1979**, 1265.
- 6) H. Takaku, T. Nomoto, Y. Sakamoto, and T. Hata, *Chem. Lett.*, **1979**, 1255.

- 7) 3: mp 146-148°C, Rf 0.41 ( $\text{CH}_2\text{Cl}_2$ -MeOH, 9:1, v/v), UV  $\lambda_{\text{max}}$  (MeOH) 266, 230 nm,  $\lambda_{\text{min}}$  (MeOH) 252 nm.  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ )  $\delta$ : 1.51 (3H, s,  $\text{CH}_3$ ), 2.75 (2H, m, H-2'), 3.22 (2H, br s, H-5'), 3.59 (6H, s,  $\text{OCH}_3$ ), 4.85 (1H, m, H-4'), 5.85 (1H, m, H-3'), 6.50 (1H, d,  $J_{1,2}$ =6Hz, H-1'), 6.68-7.98 (18H, m, ArH and H-6), 9.50 (1H, br s, NH). Anal. Calcd for  $\text{C}_{38}\text{H}_{35}\text{N}_3\text{O}_9\text{S}$ : C, 64.31; H, 4.98; N, 5.92. Found: C, 63.93; H, 5.11; N, 5.66.
- 8)  $^{31}\text{P}$ -NMR spwctroscopy (pyridine- $\text{CDCl}_3$ )  $\delta$  = +5.71 p.p.m. relative to 85%  $\text{H}_3\text{PO}_4$ .
- 9)  $^{31}\text{P}$ -NMR [(pyridine- $\text{C}_6\text{D}_6$ ), 85%  $\text{H}_3\text{PO}_4$ ] spectra of 2a-d are shown below. 2a=  $\delta$ +6.03; 2b=  $\delta$ +7.31; 2c=  $\delta$ +6.43; 2d=  $\delta$ +7.35.
- 10) W. Shelver, M. I. Blake, and C. E. Miller, J. Am. Pharm. Assoc., 47, 72 (1958).

(Received February 2, 1984)